AVNS
Avanos Medical, Inc. NYSE Listed Oct 21, 2014$24.77
Mkt Cap $1.2B
52w Low $9.30
99.8% of range
52w High $24.80
50d MA $17.47
200d MA $13.34
P/E (TTM)
-16.9x
EV/EBITDA
-16.9x
P/B
1.5x
Debt/Equity
0.2x
ROE
-9.4%
P/FCF
12.1x
RSI (14)
—
ATR (14)
—
Beta
1.05
50d MA
$17.47
200d MA
$13.34
Avg Volume
1.2M
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
5405 Windward Parkway · Alpharetta, GA 30004 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | 0.24 | 0.29 | +20.8% | 13.64 | +0.1% | +5.3% | +0.9% | -2.7% | -0.9% | +0.1% | — |
| Nov 5, 2025 | AMC | 0.12 | 0.22 | +83.3% | 10.66 | +0.7% | +4.9% | +0.4% | +1.9% | +1.9% | +0.9% | — |
| Aug 5, 2025 | AMC | 0.18 | 0.17 | -5.6% | 9.89 | +0.1% | +4.4% | +4.0% | +0.7% | -2.8% | +2.6% | — |
| May 6, 2025 | AMC | 0.19 | 0.26 | +36.8% | 12.85 | -0.1% | -2.1% | +0.0% | +0.6% | +3.6% | -3.0% | — |
| Feb 26, 2025 | AMC | 0.40 | 0.43 | +7.5% | 15.62 | -1.7% | -2.6% | -1.1% | +0.5% | -0.7% | +1.9% | — |
| Oct 30, 2024 | AMC | 0.36 | 0.36 | +0.0% | 18.58 | +1.0% | +0.5% | +0.2% | +2.7% | +3.0% | +5.9% | — |
| Jul 31, 2024 | AMC | 0.29 | 0.34 | +17.2% | 23.92 | -0.2% | -0.7% | +1.1% | -4.4% | -0.0% | -2.0% | — |
| May 2, 2024 | AMC | 0.21 | 0.22 | +4.8% | 19.71 | +1.2% | -0.2% | +0.3% | -1.0% | +0.1% | -0.5% | — |
| Feb 20, 2024 | AMC | 0.37 | 0.36 | -2.7% | 19.50 | +0.4% | +0.1% | +0.4% | +0.5% | -2.1% | +0.4% | — |
| Nov 1, 2023 | AMC | 0.29 | 0.30 | +3.4% | 20.79 | -0.6% | +3.5% | +2.6% | -1.7% | -2.4% | -0.5% | — |
| Aug 9, 2023 | AMC | 0.34 | 0.24 | -29.4% | 23.41 | -0.2% | -0.6% | -3.0% | -0.8% | -0.6% | -1.3% | — |
| May 3, 2023 | AMC | 0.28 | 0.27 | -3.6% | 24.44 | -3.7% | -3.7% | +1.8% | -2.2% | -1.8% | +1.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 25 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $25.54 | $24.29 | -4.9% | -4.3% | +1.3% | -1.8% | +0.2% | +0.3% |
| Jun 21 | Stifel | Maintains | Hold → Hold | — | $25.59 | $25.50 | -0.4% | +0.1% | +1.9% | -0.8% | -1.4% | +0.2% |
| May 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $24.44 | $23.53 | -3.7% | -3.7% | +1.8% | -2.2% | -1.8% | +1.3% |
| Feb 22 | Morgan Stanley | Maintains | Underweight → Underweight | — | $29.01 | $29.03 | +0.1% | +0.4% | +0.6% | -2.2% | -1.4% | -0.7% |
| Jan 6 | Morgan Stanley | Maintains | Underweight → Underweight | — | $26.92 | $27.23 | +1.2% | +0.5% | -0.3% | +1.7% | +1.6% | +3.7% |
| Nov 3 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $23.17 | $22.73 | -1.9% | -3.3% | +1.5% | +5.7% | -0.5% | +1.2% |
| Oct 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $20.94 | $20.62 | -1.5% | -1.1% | -4.0% | +2.0% | -1.4% | +5.3% |
| Aug 10 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $28.84 | $28.80 | -0.1% | -2.2% | +0.4% | +2.8% | +1.7% | -4.1% |
| Jul 18 | Stifel | Maintains | Hold → Hold | — | $26.85 | $26.84 | -0.0% | -1.5% | +3.6% | +0.2% | +1.8% | -0.6% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $26.30 | $26.84 | +2.1% | +2.1% | -1.5% | +3.6% | +0.2% | +1.8% |
| May 5 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.73 | $29.84 | -2.9% | -4.2% | -5.8% | -7.4% | -1.3% | -1.1% |
| Feb 24 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $31.69 | $31.48 | -0.7% | +7.2% | +4.2% | -0.0% | -1.3% | -0.9% |
| Jan 7 | Morgan Stanley | Maintains | Underweight → Underweight | — | $34.52 | $33.73 | -2.3% | -3.5% | +2.6% | -4.4% | -1.6% | +1.4% |
| Aug 4 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Aug 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Aug 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $36.93 | $35.05 | -5.1% | -8.0% | +0.2% | +2.0% | -2.2% | -1.3% |
| Jan 8 | KeyBanc | Maintains | Overweight → Overweight | — | $48.58 | $49.22 | +1.3% | -1.1% | -0.2% | +0.5% | -0.2% | +0.7% |
| Dec 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $47.27 | $48.07 | +1.7% | +1.2% | +0.5% | +3.0% | -3.0% | -3.0% |
| Nov 4 | Morgan Stanley | Maintains | Underweight → Underweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Nov 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Nov 4 | KeyBanc | Maintains | Overweight → Overweight | — | $40.32 | $40.13 | -0.5% | +0.5% | -1.6% | -0.3% | +4.4% | +2.8% |
| Aug 5 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $32.50 | $32.62 | +0.4% | -4.9% | -0.1% | +0.9% | +0.1% | +1.8% |
| Aug 5 | KeyBanc | Maintains | Overweight → Overweight | — | $32.50 | $32.62 | +0.4% | -4.9% | -0.1% | +0.9% | +0.1% | +1.8% |
| May 7 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.36 | $31.15 | +2.6% | -4.9% | -2.7% | +0.5% | -4.6% | -4.3% |
| Apr 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $29.99 | $30.32 | +1.1% | +4.9% | -2.7% | +4.9% | -3.3% | +0.1% |
| Apr 27 | KeyBanc | Maintains | Overweight → Overweight | — | $29.99 | $30.32 | +1.1% | +4.9% | -2.7% | +4.9% | -3.3% | +0.1% |
| Apr 13 | Barclays | Upgrade | Underweight → Equal Weight | — | $28.95 | $29.06 | +0.4% | -2.0% | +9.1% | -7.2% | +2.6% | +4.7% |
| Apr 1 | Stifel | Maintains | Hold → Hold | — | $26.93 | $25.49 | -5.3% | -12.8% | +4.9% | -3.5% | +8.3% | +0.8% |
| Mar 27 | Morgan Stanley | Maintains | Underweight → Underweight | — | $25.58 | $24.49 | -4.3% | -2.0% | +7.8% | -0.3% | -12.8% | +4.9% |
| Mar 23 | Stephens & Co. | Maintains | Overweight → Overweight | — | $21.14 | $21.39 | +1.2% | -2.4% | +12.5% | -1.2% | +11.5% | -2.0% |
| Dec 17 | Morgan Stanley | Maintains | Underweight → Underweight | — | $33.24 | $32.84 | -1.2% | -3.6% | +1.9% | +0.4% | -0.5% | +3.3% |
| Nov 7 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $34.27 | $34.00 | -0.8% | -1.0% | +4.7% | -3.5% | -1.5% | -3.5% |
| Nov 7 | Stifel | Downgrade | Buy → Hold | — | $34.27 | $34.00 | -0.8% | -1.0% | +4.7% | -3.5% | -1.5% | -3.5% |
| Nov 6 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Nov 6 | Raymond James | Downgrade | Outperform → Market Perform | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Nov 6 | KeyBanc | Maintains | Overweight → Overweight | — | $37.08 | $35.85 | -3.3% | -7.6% | -1.0% | +4.7% | -3.5% | -1.5% |
| Aug 7 | Raymond James | Maintains | Outperform → Outperform | — | $37.23 | $37.00 | -0.6% | -1.7% | +5.8% | -1.4% | -2.0% | -1.1% |
| Feb 27 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $50.50 | $50.15 | -0.7% | -5.7% | -1.2% | +1.7% | +1.1% | -3.1% |
| Feb 27 | KeyBanc | Maintains | Overweight → Overweight | — | $50.50 | $50.15 | -0.7% | -5.7% | -1.2% | +1.7% | +1.1% | -3.1% |
| Jan 4 | Barclays | Downgrade | Equal Weight → Underweight | — | $41.49 | $38.15 | -8.1% | -4.0% | +5.5% | +2.4% | +3.7% | +0.6% |
| Dec 18 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $47.59 | $47.60 | +0.0% | -0.4% | -5.7% | -1.6% | -2.2% | -4.3% |
| Dec 18 | KeyBanc | Maintains | Overweight → Overweight | — | $47.59 | $47.60 | +0.0% | -0.4% | -5.7% | -1.6% | -2.2% | -4.3% |
| Oct 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $61.48 | $61.10 | -0.6% | -3.3% | -0.0% | +0.9% | +2.8% | +0.6% |
| Aug 21 | Raymond James | Upgrade | Market Perform → Outperform | — | $66.05 | $69.60 | +5.4% | +5.5% | +2.7% | +0.6% | +0.4% | -0.2% |
| Aug 8 | Morgan Stanley | Maintains | Underweight → Underweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
| Aug 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
| Aug 8 | KeyBanc | Maintains | Overweight → Overweight | — | $65.75 | $65.50 | -0.4% | -3.0% | -1.0% | -0.6% | -0.3% | +1.1% |
No insider trades available.
8-K · 2.02
!! High
Avanos Medical, Inc. -- 8-K 2.02: Earnings Results
Avanos Medical reported Q1 2026 earnings on May 5, 2026, providing investors with updated financial performance metrics and operational results for the quarter.
May 5
8-K · 1.01
!!! Very High
Unknown — 8-K 1.01: Merger Agreement
AVNS shareholders will likely face significant dilution or a below-market acquisition price, as private equity takeovers typically involve substantial management fees and leverage that prioritize buyer returns over public shareholders.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of a key executive at Avans could disrupt operational continuity and investor confidence, particularly if no qualified successor is immediately named, potentially pressuring the stock near-term.
Mar 12
8-K · 8.01
!! High
Avanos Medical, Inc. -- 8-K 8.01: Material Event / Announcement
Avanos Medical announced it will nominate Mr. Cunniff to its Board of Directors at the 2026 Annual Meeting, signaling potential strategic leadership changes.
Feb 26
8-K
Avanos Medical, Inc. -- 8-K Filing
This appears to be a routine investor relations contact update for Avanos Medical rather than a material corporate event requiring investor analysis.
Feb 24
Data updated apr 24, 2026 7:59pm
· Source: massive.com